Hello everyone, a little update for all those who are invested. I remain invested. (@Dividendenopi )
Corcept: ROSELLA data in May 2026
04.05.2026 - 09:27:41 | boerse-global.de
Corcept Therapeutics is driving forward its transformation from endocrinology to oncology specialist. Focus on clinical data and return to profitability.
Corcept Therapeutics is facing a turning point. The company is transforming itself from an endocrinology specialist into a broadly positioned oncology player. The success of this transformation will determine the future valuation on the stock market.
Commercial test run in oncology
At the center of the strategy is the rollout of Relacorilant for the treatment of ovarian cancer. Until now, the business has been based almost exclusively on therapies for Cushing's syndrome. With the second major drug, Corcept must now prove that the existing sales structure is scalable.
The expansion of the marketing and sales organization has recently weighed on the balance sheet. Higher operating costs put pressure on short-term results. Nevertheless, the management has signaled an imminent turnaround. A return to profit is expected as early as the second quarter.
Clinical data as price driver
An important date is coming up at the end of May 2026. Data from the ROSELLA trial will be presented at an oncology congress. These phase 3 results provide details on the survival benefit of a combination therapy for ovarian cancer. Positive data could significantly increase acceptance among specialists and consolidate the market position.
At the same time, the company is pressing ahead with further oncology projects. The results of the BELLA study, which is investigating a triple combination therapy, are expected by the end of the year. In the medium term, clinical evaluations for the treatment of cervical and pancreatic cancer are also planned. These could massively expand the target group for the hopeful Relacorilant.
Diversification beyond cancer
The strategy extends beyond oncology. In the second half of 2026, a phase 3 trial for the treatment of the nerve disease ALS is due to start. Earlier phase 2 data already indicated a reduction in the risk of death.
Meanwhile, another field is approaching: data from the MONARCH study on the metabolic disease MASH is due at the end of 2026. This diversification is intended to reduce dependence on the original core business. The focus is now on operational implementation. The ability to overcome bureaucratic hurdles in reimbursement and efficiently manage the transition to specialty pharmacies will have a significant impact on the business figures in the coming quarters.
